Observational Study on Patients With Hepatocellular Carcinoma (HCC)

Last updated: July 12, 2019
Sponsor: Nanfang Hospital of Southern Medical University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Digestive System Neoplasms

Abdominal Cancer

Liver Disease

Treatment

N/A

Clinical Study ID

NCT04021056
NFHCC-01
  • Ages > 16
  • All Genders

Study Summary

This is an ongoing, longitudinal, single centre, observational, retro-prospective clinical cohort study of patients with HCC in usual clinical practice. All the HCC patients diagnosed and treated in Liver Cancer Center, Nanfang Hospital are consecutively collected and followed up.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinical diagnosis of HCC;

  • Age ≥ 16 years;

  • Received treatment targeting for HCC at least once, including operation, ablation,TACE, sorafenib, radiotherapy, chemotherapy, etc;

  • Good compliance with clinical treatment.

Exclusion

Exclusion Criteria:

  • Diagnosed as other pathological types such as cholangiocarcinoma, or mixed livercancer;

  • Received only traditional Chinese medicine or symptomatic supportive treatment; (3)survival time ≤ 7 days;

  • HCC diagnosed after liver transplantation;

  • Poor compliance or important data deficient.

Study Design

Total Participants: 3000
Study Start date:
January 01, 2011
Estimated Completion Date:
December 31, 2022

Connect with a study center

  • Nanfang Hospital

    Guangzhou, Guangdong
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.